首页> 外文OA文献 >Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation

【2h】

Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation

机译：治疗中的新型MSH6突变 - 天瓣胶质母细胞瘤和包塑醛脱蛋白瘤有助于独立于MGMT启动子甲基化的替代唑胺抗性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Stephanie A. Nguyen; Owen D.M. Stechishin; H. Artee Luchman; Xueqing Q. Lun; Donna L. Senger; Stephen M. Robbins; J. Gregory Cairncross; Samuel Weiss;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Novel MSH6 mutations in treatment-na?ve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation [J] . NguyenS.A., StechishinO.D.M., LuchmanH.A., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第18期

机译：初治性胶质母细胞瘤和间变性少突胶质细胞瘤中的新型MSH6突变与替莫唑胺耐药无关，而与MGMT启动子甲基化无关
2. MGMT Promoter Methylation Status Independently Predicts Overall Survival in Anaplastic Astrocytoma in NRG Oncology/RTOG 9813: A Phase 3 Trial of Radiation Plus Nitrosourea Versus Radiation Plus Temozolomide [J] . Bell E. H., Won M., Chang S. M., International Journal of Radiation Oncology, Biology, Physics . 2017,第2Suppla期

机译：MgMT启动子甲基化状态独立地预测了NRG肿瘤学/ RTOG 9813中的气相传细胞瘤中的整体存活：辐射加硝基脲对辐射加灭菌术治疗
3. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy [J] . Li Hailong, Li Jiye, Cheng Gang, Clinical neurology and neurosurgery . 2016,第Null期

机译：IDH突变和MGMT启动子甲基化与胶质母细胞瘤多发性胶质瘤患者的假性进展和改善的预后相关，这些患者接受了基于替莫唑胺的同时和辅助放化疗
4. Multiregional Radiomics Phenotypes at MR Imaging Predict MGMT Promoter Methylation in Glioblastoma [C] . Zhi-Cheng Li, Yinsheng Chen, Qiuchang Sun World Congress on Medical Physics and Biomedical Engineering . 2019

机译：MR成像在胶质母细胞瘤中预测MGMT启动子甲基化的多径辐射瘤表
5. Overcoming Temozolomide Resistance in Glioblastoma Multiforme with MGMT-Targeting Spherical Nucleic Acids. [D] . Sita, Timothy L. 2017

机译：MGMG靶向球形核酸克服胶质母细胞瘤中替莫唑胺的耐药性。
6. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide [O] . Robert W. Rapkins, Fan Wang, HuyTram N. Nguyen, 2015

机译：MGMT启动子SNP rs16906252是胶质母细胞瘤中MGMT甲基化的危险因素可预测对替莫唑胺的反应
7. Correction: MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance [O] . 2013

机译：校正：MSH6突变在卵泡治疗过程中胶质母细胞瘤和介导蜕膜抗性

Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation

著录项

引文网络

相似文献

相关主题

期刊订阅